Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 1 · 100%

All‐cause mortality · women with hormone‐sensitive advanced breast cancer

Fulvestrant showed no clear difference in mortality compared with other endocrine treatment (high certainty).

1 finding from 1 review

Fulvestrant for hormone‐sensitive metastatic breast cancer 2017 · Cochrane Headline outcomes only
HR 0.97 [0.87, 1.09]
5 studies · 2480 participants
High